Aurora Cannabis Inc (OTCMKTS:ACBFF) together with CanniMed Therapeutics Inc. (TSX:CMED) recently made an announcement stating that there will be three Aurora Cannabis appointees joining the CanniMed Board of Directors. This decision comes only days after the successful payment of an approximate 86.8% of the outstanding and the issued Cannimed shares.
The first one is Mr. John Knowles who served as a CEO and a director of various major U.S and the Canadian stock exchanges and he helped implement major and progressive changes. Being a part of CanniMed Board of Directors he hopes to accomplish quite much. And those that know him say that he will be calling upon team work towards achievement the company goals. He boasts of a working experience of over 30 years and that will be a good thing for the business guru.
Mr. André Jérôme is the second one and the notable aspect about him was that he was responsible for the identification of potential synergies across existing and joint venture partners. That is not forgetting that he played a major role towards the integration of acquisitions. Mr. Jérôme was a member of the Bar of Québec where he served over a period of 23 years.
At Biopharma Inc he served as the company’s CEO and on the same note it is important to mention that he was one of the co-founders. The company has settled on him because of his long term experience and also his great dedication to work.
Mr. Michael Scott Dowty has a working experience of over 25 years in evaluating markets and companies in which case he has been maximizing on the value proposition in the competitive global market. He has been good when it comes to identifying profit growth, key business drivers and it is also crucial to point of to the work he has been doing towards spurring rapid revenue growth.
Mr. Michel Lamontagne is experienced in philanthropy, government relations, public affairs, planned giving and corporate governance. He is a member of the Quebec bar and sources indiacet that he joined way back in 1973. He is an expert in the financial sectors, life sciences and technology.